How Much Does Lyme Disease Cost Patients and Society?

Lyme disease can create substantial medical and productivity costs
Disseminated disease is associated with substantially higher healthcare costs
The total financial burden may exceed $1 billion annually

Short answer: A 2026 study estimated that Lyme disease-specific direct medical costs averaged $2,227 per episode. Mean costs were $695 for localized disease and $6,833 for disseminated disease. Annual healthcare costs in high-incidence states were estimated at $591 million to $1.05 billion, without including lost productivity and other indirect costs. [1]

How much does Lyme disease cost patients and society? The financial burden extends beyond physician visits and antibiotics. Patients may face out-of-pocket expenses, testing, hospitalization, travel, lost work, caregiving needs, disability, and costs related to persistent symptoms.

Recent research provides a clearer picture of current healthcare costs, while earlier studies demonstrate how lost productivity and nonmedical expenses can substantially increase the overall economic burden.

How Much Does Lyme Disease Treatment Cost?

A 2026 study by Yu and colleagues examined healthcare costs among 70,531 patients diagnosed with Lyme disease between 2016 and 2022. The investigators evaluated Lyme disease-specific costs, out-of-pocket expenses, and all-cause healthcare costs following diagnosis. [1]

Key finding: Lyme disease-specific direct medical costs averaged $2,227 per episode. Mean costs were $695 for patients with localized disease and $6,833 for patients classified as having disseminated disease. [1]

Although only 22.4% of patients were classified as having disseminated disease, they accounted for 68.9% of Lyme disease-specific direct healthcare costs. [1]

Disseminated disease included documented neurologic, cardiac, arthritic, or other manifestations beyond localized infection. It should not be interpreted as being equivalent to Post-Treatment Lyme Disease Syndrome (PTLDS).

The study was jointly funded by Pfizer and Valneva. Several authors were employees of Pfizer or Optum, which received Pfizer funding, and other authors reported consulting relationships with Pfizer. According to the published disclosure, the funders had no role in the study design, data collection or analysis, interpretation, manuscript preparation, or decision to publish. [1]

How Much Do Patients Pay Out of Pocket?

Yu and colleagues also examined patient out-of-pocket costs. Depending on the method used, the mean amount attributed to Lyme disease ranged from approximately $188 to $399. [1]

In the episode-based analysis, mean Lyme disease-specific out-of-pocket costs were:

• $107 for localized disease
• $401 for disseminated disease

These estimates came from an insured population and did not include every possible expense. The investigators noted that pharmacy costs were excluded from the Lyme disease-specific episode analysis. Uncovered treatments, travel, caregiving, and lost income were also not fully measured. [1]

How Much Does Lyme Disease Increase Overall Healthcare Costs?

The investigators compared patients diagnosed with Lyme disease with individuals who did not have a Lyme disease diagnosis.

During the six months after diagnosis, patients with Lyme disease had higher overall healthcare costs. Depending on the method used, the estimated additional direct healthcare cost associated with Lyme disease ranged from $2,227 to $5,571 per patient. [1]

In the unadjusted comparison with matched controls, mean six-month healthcare costs were $4,098 higher for patients with Lyme disease overall. The difference was $819 for localized disease and $12,978 for disseminated disease. [1]

These figures do not mean that every medical expense during follow-up was caused by Lyme disease. Claims-based studies can identify associations between a diagnosis and subsequent healthcare spending, but they cannot always determine the reason for every service.

What Is the Annual Healthcare Cost of Lyme Disease?

Yu and colleagues estimated that Lyme disease-associated healthcare costs in high-incidence states ranged from $591 million to $1.05 billion annually in 2022 dollars. Of that amount, an estimated $411 million to $771 million was attributable to disseminated disease. [1]

This calculation did not include every state or indirect societal costs such as lost productivity. The total national economic burden may therefore be greater, but its precise size remains uncertain.

What Are the Broader Societal Costs of Lyme Disease?

A 2022 study by Hook and colleagues examined medical expenses, out-of-pocket costs, nonmedical expenses, and lost productivity among patients in four high-incidence states. [2]

The investigators estimated that diagnosed Lyme disease may cost U.S. society approximately $345 million to $968 million annually in 2016 dollars. Patients with confirmed disseminated or probable Lyme disease had approximately twice the societal costs of those with confirmed localized disease. [2]

Although the illness was manageable for many patients, a smaller group experienced substantial expenses and productivity losses. The investigators noted that their national estimate did not fully capture suspected, undiagnosed, or nonacute cases. [2]

Why Can Lyme Disease Become Expensive?

The economic burden of Lyme disease extends beyond the initial medical visit and antibiotic prescription. Potential costs include:

• Physician and specialist visits
• Laboratory testing and diagnostic procedures
• Prescription and nonprescription medications
• Emergency department visits or hospitalization
• Travel to obtain medical care
• Home healthcare or caregiving assistance
• Lost work and reduced productivity
• Disability and limitations in daily functioning

Patients with disseminated disease, prolonged symptoms, or substantial functional impairment may face higher costs because medical care and productivity losses can continue beyond the initial infection.

What Did an Earlier Economic Study Find?

Zhang and colleagues examined medical records and patient surveys from five counties on Maryland’s Eastern Shore between 1997 and 2000. Patients were classified as having clinically defined early-stage Lyme disease, clinically defined late-stage Lyme disease, suspected Lyme disease, a tick bite, or another Lyme-related complaint. [3]

The mean total cost was $1,310 for clinically defined early-stage Lyme disease and $16,199 for clinically defined late-stage disease. These totals included direct medical costs, out-of-pocket medication expenses, nonmedical costs, and productivity losses. All amounts were reported in year-2000 dollars. [3]

The corresponding median costs were substantially lower:

• $397 for clinically defined early-stage Lyme disease
• $923 for clinically defined late-stage Lyme disease

The wide difference between the mean and median indicates that a relatively small number of patients accounted for a large portion of the total economic burden. [3]

What Costs Were Included in the Earlier Study?

For clinically defined early-stage Lyme disease, the mean total cost included:

• $801 in direct medical costs
• $259 in out-of-pocket prescription and nonprescription medication costs
• $52 in nonmedical expenses
• $196 in productivity losses

For clinically defined late-stage Lyme disease, the mean total cost included:

• $1,872 in direct medical costs
• $434 in out-of-pocket prescription and nonprescription medication costs
• $5,109 in nonmedical expenses
• $8,785 in productivity losses

The late-stage group included patients with neurologic, cardiac, and arthritic manifestations, along with patients described by the investigators as having chronic Lyme disease. It was not a group consisting exclusively of patients with PTLDS. [3]

The researchers also acknowledged that information about nonmedical expenses and productivity losses came from a relatively small subset of participants. The results were then extrapolated to the larger study population.

The Financial Impact of Persistent Lyme Disease Symptoms

Some patients experience prolonged fatigue, pain, cognitive difficulties, or impaired functioning after treatment for Lyme disease. These symptoms may lead to additional medical evaluations, reduced work capacity, travel expenses, and other costs.

Aucott and colleagues followed patients treated with three weeks of doxycycline for physician-documented erythema migrans. At six months, 36% reported new-onset fatigue, 20% reported widespread pain, and 45% reported neurocognitive difficulties. Patients classified as having PTLDS had significantly lower functioning than patients without PTLDS. [4]

The 36% finding applies to this particular research cohort and should not be interpreted as the universal PTLDS rate. Published estimates vary depending on the population, case definition, treatment timing, and methods used.

A systematic review by Mac and colleagues estimated that annual medical costs attributable to Lyme disease and PTLDS could range from approximately $712 million to $1.3 billion in the United States. The authors also emphasized the considerable uncertainty and methodological differences among the available studies. [5]

Can Symptoms Continue for More Than a Decade?

Weitzner and colleagues examined patients 11 to 20 years after treatment for culture-confirmed early Lyme disease. They reported persistent symptoms meeting their study definition in a minority of participants, including 12.3% of women and 9.9% of men. [6]

The study did not calculate the financial burden associated with those symptoms. The long-term costs of impaired functioning, lost opportunities, pain, suffering, and reduced quality of life remain difficult to measure.

How Many People Are Diagnosed and Treated for Lyme Disease?

The CDC estimates that approximately 476,000 people are diagnosed and treated for Lyme disease annually in the United States. This estimate was derived from insurance claims and represents the number of people diagnosed and treated rather than the number of confirmed cases reported through public health surveillance. [7]

The figure should therefore be interpreted carefully. It reflects the healthcare burden associated with Lyme disease diagnoses but does not mean that every diagnosis was independently confirmed.

Could the Total Burden Exceed $1 Billion?

Published analyses support an annual burden ranging from hundreds of millions of dollars to more than $1 billion, depending on the population, geographic area, and types of costs included. [1,2,5]

The 2026 estimate of $591 million to $1.05 billion included direct healthcare costs in high-incidence states but did not include every state or indirect costs such as lost productivity. [1]

The complete societal burden could be higher because economic analyses may not fully capture:

• Delayed or missed diagnoses
• Costs occurring beyond the study period
• Household productivity losses
• Unpaid caregiving
• Pain and suffering
• Reduced educational and employment opportunities
• Expenses incurred outside insurance systems

However, the available studies should not be combined through a simple mathematical extrapolation. PTLDS, disseminated Lyme disease, and clinically defined late-stage Lyme disease represent different populations, and the studies used different definitions, time periods, and cost methods.

Frequently Asked Questions

How much does Lyme disease treatment cost?

A 2026 study found mean Lyme disease-specific direct medical costs of $2,227 per episode. The mean was $695 for localized disease and $6,833 for disseminated disease. Individual costs can vary substantially. [1]

How much do Lyme disease patients pay out of pocket?

The 2026 study estimated mean out-of-pocket costs ranging from approximately $188 to $399, depending on the analytical method. In its episode-based analysis, mean out-of-pocket costs were $107 for localized disease and $401 for disseminated disease. [1]

Why is Lyme disease more expensive when it disseminates?

Disseminated disease may involve neurologic, cardiac, or joint manifestations that require additional testing, specialist care, hospitalization, or longer follow-up. Although disseminated cases represented 22.4% of patients in the 2026 study, they accounted for 68.9% of Lyme disease-specific direct healthcare costs. [1]

Does PTLDS increase healthcare costs?

Persistent fatigue, pain, cognitive difficulties, and reduced functioning may lead to additional healthcare use and productivity losses. However, the financial burden specifically attributable to PTLDS remains incompletely measured. [4,5]

What is the annual economic impact of Lyme disease?

The 2026 study estimated $591 million to $1.05 billion in annual healthcare costs in high-incidence states. A separate study estimated an annual societal burden of $345 million to $968 million. These estimates measure different populations and types of costs and should not be treated as directly interchangeable. [1,2]

Does the CDC estimate 476,000 confirmed cases each year?

No. The estimate represents approximately 476,000 people diagnosed and treated for Lyme disease annually based on insurance claims. It differs from the number of cases reported through public health surveillance. [7]

Clinical Perspective

Economic studies consistently demonstrate that Lyme disease imposes a meaningful burden on patients and society. Many patients with localized disease have relatively limited healthcare expenses, while a smaller group with disseminated disease, persistent symptoms, or impaired functioning accounts for a disproportionate share of the total burden.

The 2026 study provides current evidence that disseminated Lyme disease is associated with substantially higher direct healthcare costs. Earlier studies add an important societal perspective by documenting lost productivity, travel expenses, caregiving needs, and other nonmedical costs.

Clinical Takeaway

Lyme disease can create substantial medical, nonmedical, and productivity costs. A 2026 study found that Lyme disease-specific direct medical costs averaged $2,227 per episode, increasing from $695 for localized disease to $6,833 for disseminated disease.

Annual healthcare costs in high-incidence states were estimated at $591 million to $1.05 billion. Because that estimate did not include every state or indirect costs such as lost productivity, the complete societal burden may be greater. The findings demonstrate the economic importance of prevention and of understanding why disseminated disease accounts for a disproportionate share of healthcare costs. The study did not determine whether earlier diagnosis or treatment would have prevented dissemination or reduced costs.

Related Articles

What Is Post-Treatment Lyme Disease Syndrome (PTLDS)?

Persistent Lyme Disease Symptoms

Recovery From Lyme Disease

Lyme Disease Symptoms Guide

References

1. Yu H, Fee RM, Campfield BT, et al. Lyme disease and health care costs. JAMA Netw Open. 2026;9(1):e2552518.
2. Hook SA, Jeon S, Niesobecki SA, et al. Economic burden of reported Lyme disease in high-incidence areas, United States, 2014-2016. Emerg Infect Dis. 2022;28(6):1170-1179.
3. Zhang X, Meltzer MI, Peña CA, Hopkins AB, Wroth L, Fix AD. Economic impact of Lyme disease. Emerg Infect Dis. 2006;12(4):653-660.
4. Aucott JN, Rebman AW, Crowder LA, Kortte KB. Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: Is there something here? Qual Life Res. 2013;22(1):75-84.
5. Mac S, da Silva SR, Sander B. The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review. PLoS One. 2019;14(1):e0210280.
6. Weitzner E, Visintainer P, Wormser GP. Comparison of males versus females with culture-confirmed early Lyme disease at presentation and at 11-20 years after diagnosis. Diagn Microbiol Infect Dis. 2016;85(4):493-495.
7. Kugeler KJ, Schwartz AM, Delorey MJ, Mead PS, Hinckley AF. Estimating the frequency of Lyme disease diagnoses, United States, 2010-2018. Emerg Infect Dis. 2021;27(2):616-619.

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention